Patents by Inventor John Binder
John Binder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964818Abstract: A refuse vehicle includes a chassis, a body assembly coupled to the chassis where the body assembly defines a refuse compartment, and a lift assembly pivotably coupled to the body assembly. The lift assembly includes a first lift arm, a second lift arm, a pin having a first end coupled to the first lift arm and an opposing second end coupled to the second lift arm, a pair of forks pivotably coupled to the first lift arm and the second lift arm, an electric lift actuator coupled to the pin, and an electric fork actuator coupled to the pair of forks. The electric lift actuator is configured to rotate the pin to lift the first lift arm and the second lift arm. The electric fork actuator is configured to pivot the pair of forks relative to the first lift arm and the second lift arm.Type: GrantFiled: May 11, 2023Date of Patent: April 23, 2024Assignee: Oshkosh CorporationInventors: Joshua D. Rocholl, Derek A. Wente, John T. Kellander, Cody D. Clifton, Vincent Hoover, Zachary L. Klein, Clinton T. Weckwerth, Skylar A. Wachter, Andrew Kotloski, Wallace Buege, Caleb Binder, Martin J. Schimke
-
Publication number: 20240116706Abstract: A refuse vehicle includes a chassis, a body assembly, and a tailgate. The body assembly is coupled to the chassis and defines a refuse compartment configured to store refuse material. The tailgate comprises a refuse receiving portion, a thresher assembly, and an electrically driven actuation mechanism. The refuse receiving portion is configured to receive refuse material. The thresher assembly includes a compaction thresher including a plurality of tines and a plurality of tine springs configured to bias the plurality of tines in a direction of compaction. The plurality of tine springs are each disposed around a corresponding tine of the plurality of tines. The electrically driven actuation mechanism is configured to selectively actuate the thresher assembly.Type: ApplicationFiled: December 15, 2023Publication date: April 11, 2024Applicant: Oshkosh CorporationInventors: Joshua D. Rocholl, Derek A. Wente, John T. Kellander, Cody D. Clifton, Vincent Hoover, Zachary L. Klein, Clinton T. Weckwerth, Skylar A. Wachter, Andrew Kotloski, Wallace Buege, Caleb Binder, Martin J. Schimke
-
Patent number: 11919708Abstract: A refuse vehicle comprises a chassis, a body assembly, a battery system, and a side-loading lift assembly. The body assembly is coupled to the chassis and defines a refuse compartment configured to store refuse material. The battery system is configured to be charged via at least one of an on-board electrical energy generator, an external power source, or a power regenerative braking system. The side-loading lift assembly comprises a refuse container engagement mechanism and at least one electrically-driven actuation mechanism. The refuse container engagement mechanism is configured to selectively engage a refuse container. The at least one electrically-driven actuation mechanism is powered by the battery system and is configured to selectively actuate the side-loading lift assembly between an extended position, a retracted position, and a refuse-dumping position.Type: GrantFiled: October 25, 2022Date of Patent: March 5, 2024Assignee: Oshkosh CorporationInventors: Joshua D. Rocholl, Derek A. Wente, John T. Kellander, Cody D. Clifton, Vincent Hoover, Zachary L. Klein, Clinton T. Weckwerth, Skylar A. Wachter, Andrew Kotloski, Wallace Buege, Caleb Binder, Martin J. Schimke
-
Publication number: 20230201283Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.Type: ApplicationFiled: January 5, 2021Publication date: June 29, 2023Inventors: Joseph John Binder, Michael Dale Eisenbraun, Douglas Hanahan, David H. Kirn, Clare Lees, Prajit Limsirichai, Liliana Maruri Avidal
-
Publication number: 20220323558Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: May 13, 2021Publication date: October 13, 2022Applicant: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20220033784Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.Type: ApplicationFiled: July 9, 2021Publication date: February 3, 2022Applicant: Pfizer Inc.Inventors: Joseph John Binder, Michael Dale Eisenbraun, Clare Lees, Jeremy Shawn Myers, James Travis Patterson
-
Patent number: 11173196Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: GrantFiled: August 23, 2018Date of Patent: November 16, 2021Assignee: Pfizer Inc.Inventor: Joseph John Binder
-
Patent number: 11110158Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: August 8, 2018Date of Patent: September 7, 2021Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai, James Richard Merson
-
Patent number: 11058753Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: GrantFiled: January 18, 2019Date of Patent: July 13, 2021Assignee: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20190142918Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 18, 2019Publication date: May 16, 2019Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Patent number: 10251944Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: GrantFiled: January 17, 2017Date of Patent: April 9, 2019Assignee: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20190038728Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: August 8, 2018Publication date: February 7, 2019Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai, James Richard Merson
-
Publication number: 20190016775Abstract: The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: July 9, 2018Publication date: January 17, 2019Inventors: Joseph John Binder, Helen Kim Cho, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Marianne Marcela Andrea Martinic
-
Publication number: 20180369352Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: ApplicationFiled: August 23, 2018Publication date: December 27, 2018Inventor: Joseph John BINDER
-
Patent number: 10092636Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: GrantFiled: May 4, 2016Date of Patent: October 9, 2018Assignee: Pfizer Inc.Inventor: Joseph John Binder
-
Publication number: 20170202938Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 17, 2017Publication date: July 20, 2017Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20160375115Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: July 11, 2016Publication date: December 29, 2016Inventors: Joseph John BINDER, Helen Kim CHO, Michael Robert DERMYER, Karin Ute JOOSS, Brian Gregory PIERCE, Joyce Tsi TAN, Van To TSAI
-
Patent number: 9468672Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: March 13, 2015Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
-
Publication number: 20160235829Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: ApplicationFiled: May 4, 2016Publication date: August 18, 2016Inventor: Joseph John BINDER
-
Patent number: 9402901Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: GrantFiled: October 29, 2014Date of Patent: August 2, 2016Assignee: Pfizer Inc.Inventor: Joseph John Binder